PSA density is superior than PSA and Gleason score for adverse pathologic features prediction in patients with clinically localized prostate cancer

Journal of the Canadian Urological Association

Volumn 6, Issue 1, 2012, Pages 46-50

  Sfoungaristos, Stavros ^a   Perimenis, Petros ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84857304897     PISSN: 19116470     EISSN: None     Source Type: Journal    
DOI: 10.5489/cuaj.11079     Document Type: Article

References (18)

1. Eidenreich A, Bellmunt J, Bolla M, et al. EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease. Eur Urol 2011;59:61-71. Epub 2010 Oct 28. http://dx.doi.org/10.1016/j.eururo.2010.10.039
2. McSherry SA, Levy F, Schiebler ML, et al. Preoperative prediction of pathological tumour volume and stage in clinically localized prostate cancer: comparison of digital rectal examination, transrectal ultrasonography and magnetic resonance imaging. J Urol 1991;146:85-9.
3. Smith JA Jr, Scardino PT, Resnick MI, et al. Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial. J Urol 1997;157:902-6. http://dx.doi.org/10.1016/S0022-5347(01)65079-1
4. Stamey TA, Johnstone IM, McNeal JE, et al. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. J Urol 2002;167:103-11. http://dx.doi.org/10.1016/S0022-5347(05)65392-X
5. Makarov DV, Trock BJ, Humphreys EB, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007;69:1095-101. http://dx.doi.org/10.1016/j. urology.2007.03.042
6. Benson MC, Whang IS, Pantuck A, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992;147:815-6.
7. Wolff JM, Boeckmann W, Mattelaer P, et al. Determination of prostate gland volume by transrectal ultrasound: correlation with radical prostatectomy specimens. Eur Urol 1995;28:10-2.
8. Kundu SD, Roehl KA, Yu X, et al. Prostate specific antigen density correlates with features of prostate cancer aggressiveness. J Urol 2007;177:505-9. http://dx.doi.org/10.1016/j.juro.2006.09.039
9. Freedland SJ, Wieder JA, Jack GS, et al. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. J Urol 2002;168:110-5. http://dx.doi.org/10.1016/S0022-5347(05)64841-0
10. Freedland SJ, Kane CJ, Presti JC Jr, et al. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base. J Urol 2003;169:969-73. http://dx.doi.org/10.1097/01.ju.0000051400.85694.bb
11. Radwan MH, Yan Y, Luly JR, et al. Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure. Urology 2007;69:1121-7. http://dx.doi.org/10.1016/j.urology.2007.01.087
12. Brassell SA, Kao TC, Sun L, et al. Prostate-specific antigen versus prostate-specific antigen density as predictor of tumour volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer. Urology 2005;66:1229-33. http://dx.doi.org/10.1016/j.urology.2005.06.106
13. Taneja SS, Hsu EI, Cheli CD, et al. Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis. Urology 2002;60:10-7. http://dx.doi.org/10.1016/S0090-4295(02)01720-X
14. Aslan G, Irer B, Kefi A, et al. The value of PSA, free-to-total PSA ratio and PSA density in the prediction of pathologic stage for clinically localized prostate cancer. Int Urol Nephrol 2005;37:511-4. http://dx.doi.org/10.1007/s11255-005-0921-x
15. Ou YC, Chen JT, Yang CR, et al. Preoperative prediction of extracapsular tumour extension at radical retropubic prostatectomy in Taiwanese patients with T1c prostate cancer. Jpn J Clin Oncol 2002;32:172-6. http://dx.doi.org/10.1093/jjco/hyf036
16. Horiguchi A, Nakashima J, Horiguchi Y, et al. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer. Prostate 2003;56:23-9. http://dx.doi.org/10.1002/pros.10239
17. Horninger W, Rogatsch H, Reissigl A, et al. Correlation between preoperative predictors and pathologic features in radical prostatectomy specimens in PSA-based screening. Prostate 1999;40:56-61. http:// dx.doi.org/10.1002/(SICI)1097-0045(19990615)40:1<56::AID-PROS7>3.0.CO2-E
18. Custovic Z, Kraus O, Tomaskovic I, et al. Serum tPSA, cPSA, related density parameters and chromogranin A as predictors of positive margins after radical prostatectomy. Anticancer Res 2007;27:2817-21.